Lexaria Bioscience (LEXX) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free LEXX Stock Alerts $3.39 +0.27 (+8.65%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, EpilepsyMay 21, 2024 | finance.yahoo.comLexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyMay 20, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal StudyMay 17, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing MarketsMay 17, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 10, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, IssuanceMay 9, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2May 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)May 8, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyMay 7, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 DrugsApril 30, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceApril 17, 2024 | msn.comLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 5, 2024 | morningstar.comLexaria Bioscience Corp LEXXMarch 19, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 15, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerMarch 7, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 5, 2024 | msn.comLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 4, 2024 | finanznachrichten.deLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.com7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 1, 2024 | msn.comLexaria slips despite FDA nod to test blood pressure drugFebruary 18, 2024 | finance.yahoo.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 16, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finance.yahoo.comLexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 13, 2024 | theglobeandmail.comLexaria Bioscience’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 DrugJanuary 30, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) To Hit High Ground in Q2/Q3 2024 with Animal, Human GLP-1 StudiesJanuary 30, 2024 | finance.yahoo.comLexaria's Submits Investigational New Drug ApplicationJanuary 22, 2024 | finance.yahoo.comLEXX’ Sweet Opportunity in GLP-1sJanuary 22, 2024 | investorplace.comLEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024January 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramJanuary 16, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Looking to Grow Revenue, Commercial Opportunities Through LicensingJanuary 10, 2024 | finanznachrichten.deNetworkNewsWire: GLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsJanuary 9, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformJanuary 8, 2024 | finanznachrichten.deNetworkNewsWire: Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsJanuary 4, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug SemaglutideJanuary 4, 2024 | msn.comLexaria Slides on New Drug DevelopmentsJanuary 4, 2024 | finance.yahoo.comLexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug SemaglutideDecember 7, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Investigational New Drug Application Filing UpdateDecember 7, 2023 | finance.yahoo.comLexaria's Investigational New Drug Application Filing UpdateDecember 1, 2023 | seekingalpha.comLexaria Bioscience files to sell 1.62M for its holdersNovember 28, 2023 | theglobeandmail.comLexaria (NASDAQ: LEXX) Tech Lowers Blood Glucose More Effectively than Semaglutide AloneNovember 28, 2023 | benzinga.comLexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot StudyNovember 28, 2023 | finance.yahoo.comLexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot StudyOctober 31, 2023 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsOctober 12, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Granted Two New Patents in CanadaOctober 12, 2023 | finance.yahoo.comLexaria Granted Two New Patents in CanadaOctober 4, 2023 | theglobeandmail.comLexaria Bioscience’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competition Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution LEXX Media Mentions By Week LEXX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LEXX News Sentiment▼1.340.85▲Average Medical News Sentiment LEXX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LEXX Articles This Week▼41▲LEXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: UNCY News Today VYNE News Today JAGX News Today FBIO News Today EYEN News Today DRRX News Today RVPH News Today CARA News Today NRXP News Today MRKR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LEXX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyHow Biden has already won 2024Porter & CompanyNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss Ratings41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
